Moreover, several studies have demonstrated that mutant KRAS also drives metabolic adaptations in cancers (Son et al, 2013; Kim et al, 2020; Ying et al, 2012; Kerr et al, 2016) and that KRAS-driven metabolic reprogramming depends on the tissue of origin (Mayers et al, 2016; Gwinn et al, 2018), KRAS copy number (Kerr et al, 2016) and mutation (Varshavi et al, 2020), also reviewed in Kerk et al (2021). This evidence concerns the gene KRAS and cancer.